BioSpace News Archive

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced expanded access to its virtual ordering platforms and remote testing capabilities across its reproductive, oncology and organ transplant businesses.

Therapix Biosciences Ltd. (Nasdaq: TRPX) (the “Company”), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today that it has entered into a securities purchase agreement pursuant to which it will make a private placement (the “Private Placement”) to its Chairman and Interim Chief Executive officer of convertible promissory notes

The Prime Minister will address Canadians on the COVID-19 situation, and a media availability will follow.

Quantzig, a global data analytics and advisory firm, that delivers actionable analytics solutions to resolve complex business problems analyzes the reasons behind the growing adoption of clinical trial data analytics.

The Lupus Foundation of America’s National Lupus Advocacy Summit held March 16 – 17 was reimagined to a digital event and drew thousands of lupus advocates from across the nation to urge Capitol Hill to increase funding for lupus research and education programs

Trinity Life Sciences, a leader in global life sciences solutions, announces the availability of Trinity EthnoCapture, a digital approach to understanding the patient journey.

Global health and hygiene company RB, maker of Lysol, Air Wick, Mucinex, Enfamil and more, announced a collaboration with life sciences knowledge discovery platform company Eagle Genomics.

Infiniti Research, a leading market intelligence solutions provider, has recently announced the completion of its latest success story on product development strategy.

Ocean Bio-Chem, Inc. (NASDAQ: OBCI), has announced that its subsidiary manufacturing plant, Kinpak Inc. in Montgomery, Alabama has increased its number of shifts and is actively hiring additional personnel to try and meet overwhelming demand for its disinfectant product Performacide ® . In addition, they have taken steps t

Receptor Life Sciences (“RLS”), a leading biopharmaceutical company developing FDA regulated oral and inhaled cannabinoid medicines, today announced that the United States Patent and Trademark Office has issued the Company a Patent for compositions comprising cannabinoids and the company’s oral absorption enhancing excipients: U.S. Patent No. 10,588,974.